The randomized, double-blind, placebo-controlled clinical study in Beverly Hills, California has enrolled 12 patients undergoing laser skin ablation. In addition to assessing safety endpoints, the study is investigating efficacy endpoints, among them the promotion of wound healing and cosmetic outcomes.
The strategic priorities for GLYC-101 include wound healing following laser ablation, burn wounds, surgical wounds, venous ulcers and diabetic ulcers.